Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
Objectives China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be estab...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e052682.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846129105909579776 |
|---|---|
| author | Haitao Wang Wenchuan Shi Xiaoli Cheng Xiao Zang |
| author_facet | Haitao Wang Wenchuan Shi Xiaoli Cheng Xiao Zang |
| author_sort | Haitao Wang |
| collection | DOAJ |
| description | Objectives China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China.Design Systematic review and narrative synthesisData sources PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021Eligibility criteria for selecting studies Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review.Data extraction and synthesis We extracted information from the selected studies focusing on cost-effectiveness results of various vaccination programmes, key contextual and methodological factors influencing cost-effectiveness estimates and an assessment of study quality.Results A total of 14 studies were included for review. Considerable heterogeneity was found in terms of the methodologies used, HPV vaccination strategies evaluated and study quality. The reviewed studies generally supported the cost-effectiveness of HPV vaccine in China, although some reached alternative conclusions, particularly when assessed incremental to cervical cancer screening. Cost of vaccination was consistently identified as a key determinant for the cost-effectiveness of HPV vaccination programmes.Conclusions Implementing HPV vaccination programmes should be complemented with expanded cervical cancer screening, while the release of lower-priced domestic vaccine offers more promising potential for initiating public HPV vaccination programmes. Findings of this study contributes important evidence for policies for cervical cancer prevention in China and methodological implications for future modelling efforts. |
| format | Article |
| id | doaj-art-6980c0a23f5946dd8dad882af08979b4 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-6980c0a23f5946dd8dad882af08979b42024-12-10T08:40:08ZengBMJ Publishing GroupBMJ Open2044-60552021-12-01111210.1136/bmjopen-2021-052682Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studiesHaitao Wang0Wenchuan Shi1Xiaoli Cheng2Xiao Zang3Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USASchool of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaDongfang Hospital, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USAObjectives China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China.Design Systematic review and narrative synthesisData sources PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021Eligibility criteria for selecting studies Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review.Data extraction and synthesis We extracted information from the selected studies focusing on cost-effectiveness results of various vaccination programmes, key contextual and methodological factors influencing cost-effectiveness estimates and an assessment of study quality.Results A total of 14 studies were included for review. Considerable heterogeneity was found in terms of the methodologies used, HPV vaccination strategies evaluated and study quality. The reviewed studies generally supported the cost-effectiveness of HPV vaccine in China, although some reached alternative conclusions, particularly when assessed incremental to cervical cancer screening. Cost of vaccination was consistently identified as a key determinant for the cost-effectiveness of HPV vaccination programmes.Conclusions Implementing HPV vaccination programmes should be complemented with expanded cervical cancer screening, while the release of lower-priced domestic vaccine offers more promising potential for initiating public HPV vaccination programmes. Findings of this study contributes important evidence for policies for cervical cancer prevention in China and methodological implications for future modelling efforts.https://bmjopen.bmj.com/content/11/12/e052682.full |
| spellingShingle | Haitao Wang Wenchuan Shi Xiaoli Cheng Xiao Zang Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies BMJ Open |
| title | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
| title_full | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
| title_fullStr | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
| title_full_unstemmed | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
| title_short | Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies |
| title_sort | cost effectiveness of human papillomavirus vaccine in china a systematic review of modelling studies |
| url | https://bmjopen.bmj.com/content/11/12/e052682.full |
| work_keys_str_mv | AT haitaowang costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT wenchuanshi costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT xiaolicheng costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies AT xiaozang costeffectivenessofhumanpapillomavirusvaccineinchinaasystematicreviewofmodellingstudies |